Carrier Free, Recombinant, ExactAb™, Low Endotoxin, Azide Free, Validated, Animal Free, ≥95%(SDS-PAGE&SEC-HPLC), See COA Animal Free,Azide Free,Carrier Free,ExactAb™,Low Endotoxin,Recombinant,Validated for sensitive chromatographic and analytical workflows requiring minimal baseline interference.
Store at -80°C,Avoid repeated freezing and thawing Ships Dry ice packs + Cold packs Check lot-specific COA for exact specifications.
SDS, COA, datasheet, and spec sheet available for download. Lot-specific COA accessible via lot number lookup.
Cited in 1 peer-reviewed publications across chromatography, organic synthesis, and cross-coupling reactions.
Bapineuzumab (anti-APP) is an anti-β-amyloid protein (APP) recombinant monoclonal antibody. Bapineuzumab can be used for the research of Alzheimer’s disease (AD).
Purity
>95% (SDS-PAGE&SEC)
Endotoxin Level
< 1.0EU/mg
Bapineuzumab (anti-APP) (Ab170466) - ELISA
Immobilized hu-Amyloid β-Peptide (1-40) at 2.0 μg/mL can bind Bapineuzumab (anti-APP) (Ab170466) with the EC₅₀ of 152.0 ng/mL.
Bapineuzumab (anti-APP) (Ab170466) - SEC
The purity of Bapineuzumab (anti-APP) (Ab170466) is more than 95% verified by HPLC.
Comprehensive hazard, handling, storage, and regulatory compliance document.
Download SDS →Lot-specific quality data. Enter your lot number to retrieve the exact COA.
Look up COA →Full quality attributes and acceptance criteria for this grade.
View spec sheet →| Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
|---|
Find and download the COA for your product by matching the lot number on the packaging.
| Lot Number | Certificate Type | Date | Item |
|---|---|---|---|
 ZJ24F0303684 | Certificate of Analysis | Mar 25, 2024 | Ab170466 |
| ZJ24F0303683 | Certificate of Analysis | Mar 25, 2024 | Ab170466 |
| ZJ24F0303682 | Certificate of Analysis | Mar 25, 2024 | Ab170466 |
| 1. Xiaoming Zha, Doriano Lamba, Lili Zhang, Yinghan Lou, Changxu Xu, Di Kang, Li Chen, Yungen Xu, Luyong Zhang, Angela De Simone, Sarah Samez, Alessandro Pesaresi, Jure Stojan, Manuela G. Lopez, Javier Egea, Vincenza Andrisano, Manuela Bartolini. (2015) Novel Tacrine–Benzofuran Hybrids as Potent Multitarget-Directed Ligands for the Treatment of Alzheimer’s Disease: Design, Synthesis, Biological Evaluation, and X-ray Crystallography. JOURNAL OF MEDICINAL CHEMISTRY, [PMID:26632651] [10.1021/acs.jmedchem.5b01119] |
Our grade selection guide covers purity, stabilizer status, and application suitability for all variants in our catalog.
View Animal Free grade guide → View Carrier Free grade guide → View Recombinant grade guide → View Validated grade guide → View ExactAb™ grade guide → View Low Endotoxin grade guide → View Azide Free grade guide →
